PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10379633-3 1999 OBJECTIVE: The aim of this study was to compare the efficacy and tolerability of the new angiotensin-converting enzyme (ACE) inhibitor moexipril and the calcium antagonist nitrendipine in postmenopausal women with mild to moderate hypertension. moexipril 135-144 angiotensin I converting enzyme Homo sapiens 89-118 10379633-3 1999 OBJECTIVE: The aim of this study was to compare the efficacy and tolerability of the new angiotensin-converting enzyme (ACE) inhibitor moexipril and the calcium antagonist nitrendipine in postmenopausal women with mild to moderate hypertension. moexipril 135-144 angiotensin I converting enzyme Homo sapiens 120-123 10379633-6 1999 RESULTS: After the 8 weeks of treatment, the SSBP/SDBP reductions were -21.2/-15.2 mmHg in the moexipril group and -18.2/-13.6 mmHg in the nitrendipine group. moexipril 95-104 single stranded DNA binding protein 1 Homo sapiens 45-49 10379633-12 1999 In the patient population of postmenopausal women, the ACE inhibitor moexipril appears to have an advantage over the calcium antagonist nitrendipine with regard to tolerability. moexipril 69-78 angiotensin I converting enzyme Homo sapiens 55-58 10376852-0 1999 Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. moexipril 39-48 angiotensin I converting enzyme Homo sapiens 24-27 10376852-2 1999 The present study was designed to investigate efficacy and safety of the ACE inhibitor moexipril in comparison to placebo in hypertensive, postmenopausal women on HRT. moexipril 87-96 angiotensin I converting enzyme Homo sapiens 73-76 10376852-8 1999 Fibrinogen, an independent cardiovascular risk factor, increased after placebo (+35.0 mg/dl) and decreased after treatment with moexipril (-33.6 mg/dl), the difference, however, was not statistically significant. moexipril 128-137 fibrinogen beta chain Homo sapiens 0-10 9819786-7 1998 Reduction of SSBP/SDBP at endpoint was 14.7 +/- 1.9/10.0 +/- 1.1 and 8.7 +/- 1.9/8.4 +/- 1.1 mmHg after treatment with moexipril and atenolol, respectively. moexipril 119-128 single stranded DNA binding protein 1 Homo sapiens 13-17 9825188-0 1998 Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. moexipril 164-173 angiotensin I converting enzyme Homo sapiens 150-153 9825188-10 1998 The plasma concentrations of renin increased and of aldosterone decreased after moexipril administration. moexipril 80-89 renin Homo sapiens 29-34 9643274-0 1998 Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). moexipril 151-160 angiotensin I converting enzyme Homo sapiens 136-139 9617599-2 1998 UNLABELLED: Moexipril is a prodrug which is hydrolysed after oral administration to its active metabolite moexiprilat, an inhibitor of the angiotensin converting enzyme (ACE). moexipril 12-21 angiotensin I converting enzyme Homo sapiens 139-168 9617599-2 1998 UNLABELLED: Moexipril is a prodrug which is hydrolysed after oral administration to its active metabolite moexiprilat, an inhibitor of the angiotensin converting enzyme (ACE). moexipril 12-21 angiotensin I converting enzyme Homo sapiens 170-173 9079232-0 1997 Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. moexipril 93-116 angiotensin I converting enzyme Rattus norvegicus 53-82 9079232-1 1997 The pharmacodynamic and toxicological profile of the new angiotensin converting enzyme (ACE) inhibitor moexipril (CAS 82586-52-5) and its active diacid metabolite moexiprilat were studied in vitro as well as in vivo. moexipril 103-112 angiotensin I converting enzyme Rattus norvegicus 88-91 9079232-3 1997 Both, moexipril and moexiprilat inhibited the angiotensin I (ANG I)-induced contractions of rabbit aorta concentration-dependently, whereas contractions by other agents were not affected, indicating a high selectivity of both compounds for ACE. moexipril 6-15 angiotensin-converting enzyme Oryctolagus cuniculus 240-243 9079232-16 1997 On the cardiovascular system, the effects observed can be attributed to ACE inhibition by moexipril. moexipril 90-99 angiotensin I converting enzyme Rattus norvegicus 72-75 9079232-20 1997 The preclinical data indicate that moexipril possesses a high degree of specifity as an ACE-inhibitor without relevant side effects or gross toxicity. moexipril 35-44 angiotensin I converting enzyme Rattus norvegicus 88-91 8961074-1 1996 Moexipril is a new, long-acting angiotensin-converting enzyme (ACE) inhibitor. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 32-61 9140801-1 1997 Combination therapy with the new ACE inhibitor moexipril plus hydrochlorothiazide (HCTZ) results in significant blood pressure (BP) reductions. moexipril 47-56 angiotensin I converting enzyme Homo sapiens 33-36 9140801-8 1997 Headache and cough which are the most frequently reported AEs after treatment with ACE inhibitors were seen in 9% and 10% of the patients in the moexipril/HCTZ group compared to 10% and 4% in the metoprolol/HCTZ group. moexipril 145-154 angiotensin I converting enzyme Homo sapiens 83-86 8961074-1 1996 Moexipril is a new, long-acting angiotensin-converting enzyme (ACE) inhibitor. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 63-66 7473177-0 1995 Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. moexipril 0-9 angiotensin I converting enzyme Rattus norvegicus 48-51 8803515-1 1996 OBJECTIVE: To compare the antihypertensive efficacy of moexipril, a new angiotensin-converting enzyme (ACE) inhibitor, to treatment with hydrochlorothiazide (HCTZ). moexipril 55-64 angiotensin I converting enzyme Homo sapiens 72-101 8803515-1 1996 OBJECTIVE: To compare the antihypertensive efficacy of moexipril, a new angiotensin-converting enzyme (ACE) inhibitor, to treatment with hydrochlorothiazide (HCTZ). moexipril 55-64 angiotensin I converting enzyme Homo sapiens 103-106 8903666-2 1995 In the present study we investigated the effects of the new ACE inhibitor moexipril, 17beta-estradiol and their combination on the bone turnover in ovariectomized Sprague-Dawley rats, an established animal model for studying human postmenopausal osteoporosis. moexipril 74-83 angiotensin I converting enzyme Rattus norvegicus 60-63 8903666-14 1995 CONCLUSIONS: The results of this study show that ACE inhibition by moexipril has no effect on the skeleton when given alone and that it does not hamper the osteoprotective effects of 17beta-estradiol. moexipril 67-76 angiotensin I converting enzyme Rattus norvegicus 49-52 7473177-1 1995 The pharmacodynamic profile of the new angiotensin-converting enzyme (ACE) inhibitor moexipril and its active diacid, moexiprilat, was studied in vitro and in vivo. moexipril 85-94 angiotensin I converting enzyme Rattus norvegicus 70-73 7473177-3 1995 Upon oral administration of moexipril (10 mg/kg/day) to spontaneously hypertensive rats, plasma angiotensin II concentration decreased to undetectable levels, plasma ACE activity was inhibited by 98% and plasma angiotensin I concentration increased 8.6-fold 1 h after dosing. moexipril 28-37 angiotensinogen Rattus norvegicus 96-110 7473177-3 1995 Upon oral administration of moexipril (10 mg/kg/day) to spontaneously hypertensive rats, plasma angiotensin II concentration decreased to undetectable levels, plasma ACE activity was inhibited by 98% and plasma angiotensin I concentration increased 8.6-fold 1 h after dosing. moexipril 28-37 angiotensin I converting enzyme Rattus norvegicus 166-169 7473177-5 1995 Four-week oral administration of moexipril (0.1-30 mg/kg/day) to spontaneously hypertensive rats lowered blood pressure and differentially inhibited ACE activity in plasma, lung, aorta, heart and kidney in a dose-dependent fashion. moexipril 33-42 angiotensin I converting enzyme Rattus norvegicus 149-152 7473177-6 1995 Equidose treatment (10 mg/kg/day) with moexipril and enalapril over 4 weeks led to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin. moexipril 39-48 angiotensin I converting enzyme Rattus norvegicus 144-147 7473177-6 1995 Equidose treatment (10 mg/kg/day) with moexipril and enalapril over 4 weeks led to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin. moexipril 39-48 angiotensinogen Rattus norvegicus 172-187 7473177-7 1995 In contrast, ACE inhibition in aorta, heart and lung was significantly greater with moexipril than with enalapril, whereas in the kidney both drugs inhibited ACE activity to a similar extent. moexipril 84-93 angiotensin I converting enzyme Rattus norvegicus 13-16 7473177-8 1995 In summary, moexipril is an orally active ACE inhibitor that is comparable to enalapril in potency and duration of antihypertensive activity. moexipril 12-21 angiotensin I converting enzyme Rattus norvegicus 42-45 34631362-7 2021 Captopril, moexipril, benazepril, fosinopril, losartan, remdesivir, Sigma ACEI, NAA, and NAM interacted and docked at the interface of ACE2 and SARS-CoV-2 spike protein complex. moexipril 11-20 angiotensin converting enzyme 2 Homo sapiens 135-139 7637658-0 1995 Moexipril: another ACE inhibitor for hypertension. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 19-22 7564369-0 1995 Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension. moexipril 28-37 angiotensin I converting enzyme Homo sapiens 45-48 7564369-1 1995 Moexipril is a new nonpeptide angiotensin-converting enzyme (ACE) inhibitor with an intermediate duration of action. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 30-59 7564369-1 1995 Moexipril is a new nonpeptide angiotensin-converting enzyme (ACE) inhibitor with an intermediate duration of action. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 61-64 7608310-0 1995 Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. moexipril 59-68 angiotensin I converting enzyme Homo sapiens 44-47 7608310-1 1995 To assess the efficacy and time-dependent effects of once-daily moexipril, a nonsulfhydryl ester prodrug of the angiotensin-converting enzyme (ACE) inhibitor, moexiprilat, we conducted a multicenter, double-blind, placebo-controlled trial in 51 hypertensive patients using both clinic and ambulatory blood pressure (BP) recordings. moexipril 64-73 angiotensin I converting enzyme Homo sapiens 112-141 7608310-1 1995 To assess the efficacy and time-dependent effects of once-daily moexipril, a nonsulfhydryl ester prodrug of the angiotensin-converting enzyme (ACE) inhibitor, moexiprilat, we conducted a multicenter, double-blind, placebo-controlled trial in 51 hypertensive patients using both clinic and ambulatory blood pressure (BP) recordings. moexipril 64-73 angiotensin I converting enzyme Homo sapiens 143-146 7849255-4 1994 At this time, Group 2 continued to receive insulin alone, whereas Group 3 was also given the ACE inhibitor moexipril for 8 more wk. moexipril 107-116 angiotensin I converting enzyme Rattus norvegicus 93-96 7621306-4 1994 METHODS: We compared the effects pretreatment with the ACE inhibitor moexipril with those of the type 1 angiotensin (AT1)-receptor antagonist losartan on structural and functional cardiac parameters after myocardial infarction in rats. moexipril 69-78 angiotensin I converting enzyme Rattus norvegicus 55-58 7621306-11 1994 CONCLUSION: The cardioprotective effects of the ACE inhibitor moexipril administered before myocardial infarction in the present study were a result of the reduced breakdown of kinins rather than of the reduced synthesis of angiotensin II. moexipril 62-71 angiotensin I converting enzyme Rattus norvegicus 48-51 7621306-11 1994 CONCLUSION: The cardioprotective effects of the ACE inhibitor moexipril administered before myocardial infarction in the present study were a result of the reduced breakdown of kinins rather than of the reduced synthesis of angiotensin II. moexipril 62-71 angiotensinogen Rattus norvegicus 224-238 34421325-6 2021 Trandolapril, Benazepril, and Moexipril were evaluated as the best non-carcinogenic and non-toxic potential inhibitors of spike glycoprotein, Mpro, and RdRp, respectively. moexipril 30-39 NEWENTRY Severe acute respiratory syndrome-related coronavirus 142-146 34421325-6 2021 Trandolapril, Benazepril, and Moexipril were evaluated as the best non-carcinogenic and non-toxic potential inhibitors of spike glycoprotein, Mpro, and RdRp, respectively. moexipril 30-39 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 152-156 8569224-11 1995 Although the ACE inhibitors decreased BP (zabicipril, 9, 16, 16%; moexipril, 10, 22, 31%; enalapril, 15%) and plasma ACE activity (zabicipril, 87, 88, 92%; moexipril, 79, 92, 93%; enalapril, 88%) significantly and dose dependently, they did not reduce intimal thickening or the cross-sectional area of the media. moexipril 66-75 angiotensin-converting enzyme Oryctolagus cuniculus 13-16 8569224-11 1995 Although the ACE inhibitors decreased BP (zabicipril, 9, 16, 16%; moexipril, 10, 22, 31%; enalapril, 15%) and plasma ACE activity (zabicipril, 87, 88, 92%; moexipril, 79, 92, 93%; enalapril, 88%) significantly and dose dependently, they did not reduce intimal thickening or the cross-sectional area of the media. moexipril 156-165 angiotensin-converting enzyme Oryctolagus cuniculus 13-16 34631362-7 2021 Captopril, moexipril, benazepril, fosinopril, losartan, remdesivir, Sigma ACEI, NAA, and NAM interacted and docked at the interface of ACE2 and SARS-CoV-2 spike protein complex. moexipril 11-20 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 155-160 15662286-5 2005 The aim of this study was to evaluate the effect of a 24-week treatment with the ACE inhibitor moexipril (15 mg once daily) on the regression of LVH in hypertensive patients. moexipril 95-104 angiotensin I converting enzyme Homo sapiens 81-84 34458381-7 2021 Results: The ACE inhibitors and their analogues fosinopril (1-), fosinopril and moexipril have the best binding affinity to the protein with binding energies < - 7.0 kcal/mol while non-flavonoid stilben-4-ol binds with free binding energy of - 7.1 kcal/mol. moexipril 80-89 angiotensin I converting enzyme Homo sapiens 13-16 23473803-0 2013 Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). moexipril 45-54 phosphodiesterase 4A Homo sapiens 84-103 23473803-0 2013 Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). moexipril 45-54 phosphodiesterase 4A Homo sapiens 105-109 23473803-4 2013 With this objective, we utilised a high-throughput computational approach that identified moexipril, a well tolerated and safe angiotensin-converting enzyme (ACE) inhibitor, as a PDE4 inhibitor. moexipril 90-99 angiotensin I converting enzyme Homo sapiens 127-156 23473803-4 2013 With this objective, we utilised a high-throughput computational approach that identified moexipril, a well tolerated and safe angiotensin-converting enzyme (ACE) inhibitor, as a PDE4 inhibitor. moexipril 90-99 angiotensin I converting enzyme Homo sapiens 158-161 23473803-4 2013 With this objective, we utilised a high-throughput computational approach that identified moexipril, a well tolerated and safe angiotensin-converting enzyme (ACE) inhibitor, as a PDE4 inhibitor. moexipril 90-99 phosphodiesterase 4A Homo sapiens 179-183 23473803-5 2013 Experimentally we showed that moexipril and two structurally related analogues acted in the micro molar range to inhibit PDE4 activity. moexipril 30-39 phosphodiesterase 4A Homo sapiens 121-125 23473803-6 2013 Employing a FRET-based biosensor constructed from the nucleotide binding domain of the type 1 exchange protein activated by cAMP, EPAC1, we demonstrated that moexipril markedly potentiated the ability of forskolin to increase intracellular cAMP levels. moexipril 158-167 Rap guanine nucleotide exchange factor 3 Homo sapiens 130-135 23473803-7 2013 Finally, we demonstrated that the PDE4 inhibitory effect of moexipril is functionally able to induce phosphorylation of the small heat shock protein, Hsp20, by cAMP dependent protein kinase A. moexipril 60-69 phosphodiesterase 4A Homo sapiens 34-38 23473803-7 2013 Finally, we demonstrated that the PDE4 inhibitory effect of moexipril is functionally able to induce phosphorylation of the small heat shock protein, Hsp20, by cAMP dependent protein kinase A. moexipril 60-69 heat shock protein family B (small) member 6 Homo sapiens 150-155 23473803-8 2013 Our data suggest that moexipril is a bona fide PDE4 inhibitor that may provide the starting point for development of novel PDE4 inhibitors with an improved therapeutic window. moexipril 22-31 phosphodiesterase 4A Homo sapiens 47-51 23473803-8 2013 Our data suggest that moexipril is a bona fide PDE4 inhibitor that may provide the starting point for development of novel PDE4 inhibitors with an improved therapeutic window. moexipril 22-31 phosphodiesterase 4A Homo sapiens 123-127 18260911-0 2007 [Assessment of the effect of angiotensin converting enzyme inhibitor moexipril on the functional state of vascular wall in patients with I - III degree arterial hypertension]. moexipril 69-78 angiotensin I converting enzyme Homo sapiens 29-58 16474309-6 2006 Moexipril and spirapril caused lowering of elevated levels of leptin. moexipril 0-9 leptin Homo sapiens 62-68 16858353-0 2006 [Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome]. moexipril 97-106 angiotensin I converting enzyme Homo sapiens 57-86 16883271-3 2006 Moexipril is an ACE inhibitor which in women demonstrated its doubtless antihypertensive efficacy with additional favorable properties. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 16-19 17159885-0 2006 [Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. moexipril 41-50 angiotensin I converting enzyme Homo sapiens 1-30 17159885-2 2006 Data on efficacy and safety of angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension are reviewed. moexipril 71-80 angiotensin I converting enzyme Homo sapiens 31-60 16311918-0 2005 Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver. moexipril 47-56 angiotensin I converting enzyme Rattus norvegicus 33-36 16311918-0 2005 Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver. moexipril 47-56 catalase Rattus norvegicus 65-73 16311918-4 2005 The purpose of the study was to establish the effect of moexipril on catalase activity and to compare it with the effect of both saline controls and that of the known PPAR agonist clofibrate (positive control). moexipril 56-65 catalase Rattus norvegicus 69-77 16311918-10 2005 The number of catalase positive cells in both moexipril group (95% CI 57-61) and clofibrate group (95% CI 72-80) is higher than in controls (95% CI 3-16) (p < or = 0.01). moexipril 46-55 catalase Rattus norvegicus 14-22 16311918-11 2005 The number of catalase positive cells in the clofibrate group is higher than in the moexipril group (p < or = 0.01). moexipril 84-93 catalase Rattus norvegicus 14-22 16311918-12 2005 High-dose subchronic exposure to the ACE-inhibitor moexipril induces catalase activity in the rat liver to an extent comparable to fibrates. moexipril 51-60 angiotensin I converting enzyme Rattus norvegicus 37-40 16311918-12 2005 High-dose subchronic exposure to the ACE-inhibitor moexipril induces catalase activity in the rat liver to an extent comparable to fibrates. moexipril 51-60 catalase Rattus norvegicus 69-77 15823625-1 2005 AIM: To evaluate the effect of ACE inhibitor moexipril if added to combination therapy in patient with poorly controlled hypertension. moexipril 45-54 angiotensin I converting enzyme Homo sapiens 31-34 15823625-5 2005 If the patient fulfilled inclusion criteria, ACE inhibitor moexipril was added to the therapy and uptitrated according to BP values. moexipril 59-68 angiotensin I converting enzyme Homo sapiens 45-48 15823625-13 2005 SUMMARY: ACE inhibitor moexipril added to combination therapy of hypertension had similar effect on blood pressure reduction and left ventricle mass as in monotherapy trials. moexipril 23-32 angiotensin I converting enzyme Homo sapiens 9-12 2554270-1 1989 Moexipril [2-[(1-ethoxycarbonyl)-3-phenylpropyl]amino-1-oxopropyl]-6, 7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (S,S,S)], an ester prodrug of an ACE inhibitor, was formulated in controlled-release preparations with a range of in vitro release rates, to provide a prolonged input of drug in vivo. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 164-167 26076923-2 2016 In vitro incubation study of human liver, intestine and kidney s9 fractions demonstrated that the ACEI prodrugs enalapril, ramipril, perindopril, moexipril and fosinopril are selectively activated by CES1 in the liver. moexipril 146-155 carboxylesterase 1 Homo sapiens 200-204 17583172-5 2007 Moexipril hydrochloride is a long-acting, non-sulfhydryl ACE inhibitor that can be taken once daily for the treatment of hypertension. moexipril 0-23 angiotensin I converting enzyme Homo sapiens 57-60 11929321-3 2002 The pharmacokinetic properties of five newer ACE inhibitors (trandolapril, moexipril, spirapril, temocapril and imidapril) are reviewed in this update. moexipril 75-84 angiotensin I converting enzyme Homo sapiens 45-48 16320692-1 2005 AIM: To evaluate a hypotensive effect and metabolic neutrality and safety of ACE inhibitor moexipril in postmenopausal women with arterial hypertension (AH), influence on quality of life. moexipril 91-100 angiotensin I converting enzyme Homo sapiens 77-80 15030263-3 2003 Moexipril (Univasc, Bayer) is a long-acting ACE inhibitor suitable for once-daily administration and, like enalapril, is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, in order to become effective. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 44-47 15030263-3 2003 Moexipril (Univasc, Bayer) is a long-acting ACE inhibitor suitable for once-daily administration and, like enalapril, is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, in order to become effective. moexipril 11-18 angiotensin I converting enzyme Homo sapiens 44-47 14728069-0 2003 ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. moexipril 20-29 angiotensin I converting enzyme Homo sapiens 0-3 14728069-2 2003 Moexipril is an ACE inhibitor with a lipophilicity in the same range as quinapril, benazepril or ramipril, and so can readily penetrate lipid membranes and thus target tissue ACE in addition to plasma ACE. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 16-19 14728069-2 2003 Moexipril is an ACE inhibitor with a lipophilicity in the same range as quinapril, benazepril or ramipril, and so can readily penetrate lipid membranes and thus target tissue ACE in addition to plasma ACE. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 175-178 14728069-2 2003 Moexipril is an ACE inhibitor with a lipophilicity in the same range as quinapril, benazepril or ramipril, and so can readily penetrate lipid membranes and thus target tissue ACE in addition to plasma ACE. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 175-178 14728069-3 2003 Evidence from animal studies shows similar and significant (p < 0.05) reductions in tissue ACE activity for moexipril and quinapril. moexipril 111-120 angiotensin I converting enzyme Homo sapiens 94-97 14728069-5 2003 ACE inhibitors, including moexipril, may exert neuroprotective effects. moexipril 26-35 angiotensin I converting enzyme Homo sapiens 0-3 14728069-9 2003 Preclinical studies indicate that the renin-angiotensin-aldosterone system may play a role in the regulation of bone resorption and moexipril had no adverse effects on bone metabolism in animal models and the drug did not hamper the osteoprotective effects of estrogen. moexipril 132-141 renin Homo sapiens 38-43 14728069-10 2003 Reduction in left ventricular mass with moexipril in patients with hypertension was similar in magnitude to the effect of other ACE inhibitors. moexipril 40-49 angiotensin I converting enzyme Homo sapiens 128-131 12602539-3 2003 The aim of this study was to characterize the effects of two ACE inhibitors, moexipril and quinapril on tissue ACE activity. moexipril 77-86 angiotensin I converting enzyme Rattus norvegicus 111-114 12602539-5 2003 After single treatment, moexipril and quinapril effectively inhibited ACE activity in plasma and slightly in heart and aorta, whereas after 6 days of treatment they inhibited ACE activity in plasma (87% and 94%, respectively), lung (92% and 93%), myocardium (26% and 23%), kidney (21% and 20%), and aorta (39% and 40%), but not in skeletal muscle. moexipril 24-33 angiotensin I converting enzyme Rattus norvegicus 70-73 11918132-0 2002 Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. moexipril 64-73 angiotensin I converting enzyme Homo sapiens 50-53 15286086-3 2004 Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 27-30 15286086-3 2004 Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective. moexipril 111-120 angiotensin I converting enzyme Homo sapiens 27-30 15286086-3 2004 Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective. moexipril 111-120 angiotensin I converting enzyme Homo sapiens 95-98 11837383-0 2002 Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. moexipril 0-9 angiotensin I converting enzyme Homo sapiens 105-108 11837383-1 2002 OBJECTIVE: To characterize the lipophilic ACE inhibitor moexipril and its active metabolite moexiprilat regarding the duration of action, the susceptibility of the pharmacokinetics and pharmacodynamics to food intake and the concentration-dependent effect. moexipril 56-65 angiotensin I converting enzyme Homo sapiens 42-45 11325479-8 2001 Cyclization reactions of crystalline and amorphous angiotensin-converting enzyme (ACE) inhibitors (spirapril hydrochloride, quinapril hydrochloride, and moexipril) are presented which investigate mobility and chemical reactivity. moexipril 153-162 angiotensin I converting enzyme Homo sapiens 51-80 11325479-8 2001 Cyclization reactions of crystalline and amorphous angiotensin-converting enzyme (ACE) inhibitors (spirapril hydrochloride, quinapril hydrochloride, and moexipril) are presented which investigate mobility and chemical reactivity. moexipril 153-162 angiotensin I converting enzyme Homo sapiens 82-85